The recent approval of the dual-inhibitors (EGFR/HER2), such as lapatinib, opens a new avenue for therapeutic strategies with multitargeted drugs, not only directed against the surface receptors ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations) with blockade of EGFR, both mutations that are seen in NSCLC tumours. The oral drug was awarded ...

Sunvozertinib inhibits EGFR and HER2, potentially leading to tumor regression and is being tested in first-line settings in the WU-KONG28 trial. Priority review aims for faster FDA action on drugs ...

The extracellular domain of HER2 is unable to bind extracellular ligands and depends on heterodimerization with other ligand-activated receptors like EGFR. 3 ...the combination of lapatinib plus ...

If you continue to have this issue please contact customerservice@slackinc.com. Newer eGFR calculations that do not consider race show a link between kidney function and dementia. Equations with ...

BMBC is particularly common in breast cancers that are positive for epidermal growth factor receptor1 and 2 (EGFR and HER2), however, targeted therapies against BMBC, e.g., lapatinib - a EGFR/HER2 ...

Expert Rev Mol Diagn. 2008;8(4):417-434. Interestingly, cancers that co-overexpress EGFR and HER2 have a worse clinical outcome than those overexpressing either receptor alone. There is therefore ...

“While S1613 showed that anti-HER2 therapy was better tolerated and similarly efficacious to anti-EGFR therapy, the key finding is that the relative benefit of these therapies may depend on the ...